Gilde Healthcare appoints Jan Willem Bakker as Head of Investor Relations - Gilde Healthcare

Gilde Healthcare appoints Jan Willem Bakker as Head of Investor Relations

2. September 2024
Utrecht (the Netherlands)

Gilde Healthcare, the transatlantic specialist investment firm, is pleased to announce the addition of Jan Willem Bakker to its team as Partner & Head of Investor Relations.

Jan Willem will focus on Gilde Healthcare’s investor relations activities and contribute to the firm’s capital raising, marketing and communications efforts. With over 20 years of experience in client facing roles in financial services he brings vast experience to benefit existing and new LPs of the Gilde Healthcare platform. “We are pleased to welcome Jan Willem to our Investor Relations and Fundraising team,” said Pieter van der Meer, Managing Partner of Gilde Healthcare. “His extensive track record with institutional investors both as an LP and GP, strong industry relationships, and entrepreneurial mindset will help in strengthening our fundraising strategy and investor relationships. He will be instrumental in the foreseen expansion of our fund platform with impactful private equity strategies.”

Prior to joining Gilde Healthcare, Jan Willem was a partner at Prime Ventures having previously held senior roles at Arcano Partners and Adveq Management AG (now Schroders Capital), during his time at Adveq Jan Willem was a board member of the Dutch Private Equity association (NVP). He began his career in financial services at Kas Bank N.V. “I am very happy to join Gilde Healthcare’s ambitious team and contribute to building out its impactful platform. I look forward to collaborating with existing and prospective investors, investment and finance teams on delivering innovative and successful investment solutions to benefit a range of stakeholders.” said Jan Willem.

About Gilde Healthcare
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Mehr neuigkeiten

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
17. Oktober 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
15. Oktober 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
14. Oktober 2025